Clinical Trial

A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-10; most recent amendment 2026-04-29.
Status change: Recruiting → Active, Not Recruiting 2026-04-29
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT06732583
Lead Sponsor CanSino Biologics Inc.
Collaborators: PT Etana Biotechnologies Indonesia
Conditions Tuberculosis
Enrollment 36 participants
Start Date 2025-11-13
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-30